
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
Advertisement
Articles by Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center
Advertisement
Latest Updated Articles
Selecting a BTKi for Relapsed MCL TreatmentPublished: February 9th 2021 | Updated:
Lenalidomide and Bortezomib for Mantle Cell LymphomaPublished: January 26th 2021 | Updated:
BTK Inhibitors for Relapsed MCL: Important ConsiderationsPublished: February 9th 2021 | Updated:
Emerging BTK Inhibitors in Mantle Cell LymphomaPublished: February 23rd 2021 | Updated:
Novel Therapies in the Pipeline in Mantle Cell LymphomaPublished: March 2nd 2021 | Updated:
CAR T-Cell Therapy for R/R Mantle Cell LymphomaPublished: February 16th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5















